Compare Mesoblast Limited (MESO) vs Carparts.Com Inc (PRTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Carparts.Com Inc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Carparts.Com Inc trades at $8.59 (market cap $66.42M). The key difference: Mesoblast Limited is far larger — about 26.3× Carparts.Com Inc's market cap, and Carparts.Com Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Carparts.Com Inc for 45 Days on average.
| MESO | PRTS | |
|---|---|---|
Market Cap | $1.75B | $66.42M |
Volume | 239,027 | 40,287 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $10.00 |
52-Week Low | $13.19 | $3.88 |
Typical Hold Time | 14 Days | 45 Days |
Enterprise Value | $1.83B | $79.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
CarParts.com (PRTS) trades at $8.695, up 0.99% with a bullish technical signal. The company shows improving quarterly earnings performance, beating expectations in recent quarters, though remains unprofitable with negative margins. Revenue has declined from $676M in 2023 to $548M in 2025, but net losses are narrowing. Analyst sentiment is positive with 60% buy ratings, while technical indicators show bullish moving averages and neutral oscillators.
The outlook suggests potential recovery as earnings improve and losses narrow, supported by analyst optimism. Key risks include persistent negative cash flow, competitive pressures in auto parts e-commerce, and execution challenges in returning to profitability. The stock offers speculative upside if the company can sustain its earnings beat trend and stabilize revenue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Carparts.Com Inc
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
Read more on PRTS →
